FARINA, NICOLA
 Distribuzione geografica
Continente #
EU - Europa 589
AS - Asia 337
NA - Nord America 241
SA - Sud America 20
Totale 1.187
Nazione #
RO - Romania 263
US - Stati Uniti d'America 236
SG - Singapore 132
IT - Italia 122
CN - Cina 121
SE - Svezia 110
HK - Hong Kong 62
RU - Federazione Russa 26
DE - Germania 24
BR - Brasile 19
FI - Finlandia 19
IE - Irlanda 6
GB - Regno Unito 5
AT - Austria 4
CA - Canada 4
JP - Giappone 4
PH - Filippine 4
IN - India 3
NL - Olanda 3
BE - Belgio 2
FR - Francia 2
IR - Iran 2
LT - Lituania 2
UZ - Uzbekistan 2
AM - Armenia 1
AZ - Azerbaigian 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
MN - Mongolia 1
PK - Pakistan 1
PY - Paraguay 1
TR - Turchia 1
UA - Ucraina 1
Totale 1.187
Città #
Shanghai 72
Hong Kong 62
Singapore 42
Milan 33
Ashburn 27
Lawrence 20
Princeton 20
Boardman 17
Helsinki 16
New York 16
Moscow 14
Rome 14
Cesano Boscone 7
Nuremberg 7
Ancona 4
Dallas 4
Guangzhou 4
Los Angeles 4
Quezon City 4
Seattle 4
Shenzhen 4
Toronto 4
Ballincollig 3
Dublin 3
Falkenstein 3
Osimo 3
Poli 3
Pune 3
San Giuliano 3
Vittoria 3
York 3
Aobadai 2
Beijing 2
Bosco Chiesanuova 2
Brescia 2
Castel Mella 2
Council Bluffs 2
Dalmine 2
Florence 2
Frankfurt am Main 2
Ghent 2
Honcho 2
Lappeenranta 2
London 2
San Antonio 2
Santa Clara 2
Tashkent 2
Turin 2
Verona 2
Amsterdam 1
Anshan 1
Antakya 1
Baku 1
Baraúna 1
Belo Horizonte 1
Bologna 1
Brasília 1
Cabo Frio 1
Campos do Jordão 1
Capão da Canoa 1
Chapadinha 1
Concórdia 1
Conselheiro Lafaiete 1
Espumoso 1
Feira de Santana 1
Formiga 1
Giv‘atayim 1
Guaramirim 1
Hangzhou 1
Harbin 1
Isfahan 1
Itamaraju 1
Jimo 1
Kingston 1
Manassas 1
Modena 1
Nantong 1
Naples 1
Newark 1
Paris 1
Pindaré Mirim 1
Rio Bonito 1
San Mateo 1
Santa Rita 1
Sete Lagoas 1
Taizhou 1
Trentola-Ducenta 1
Trumbull 1
Três Lagoas 1
Ulan Bator 1
Vienna 1
Várzea Grande 1
Washington 1
Weitang 1
Wuhan 1
Yerevan 1
Totale 509
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 286
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 48
Biobanking for COVID-19 research 46
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 44
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia 43
Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study 41
Obesity and its role in the management of rheumatoid and psoriatic arthritis 41
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 39
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 36
POS0726 POST-TRAUMATIC STRESS DISORDER AND QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. A CROSS SECTIONAL WEB SURVEY-BASED STUDY 36
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 35
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 34
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 33
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 31
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 30
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 29
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function 29
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 28
Drug retention rates of biological agents in adult onset Still's disease 28
COVID-19: Pharmacology and kinetics of viral clearance 27
Current treatment options and safety considerations when treating adult-onset Still’s disease 27
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 25
Loss of circulating CD8+ CD161high T cells in primary progressive multiple sclerosis 25
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis 25
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 24
Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year 22
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 21
Low prevalence of arrhythmias in clinically stable COVID-19 patients 21
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 21
Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort 20
Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle 16
Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature 16
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 13
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 13
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 8
Totale 1.261
Categoria #
all - tutte 10.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.533


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 0 0 0 0 2 7 1
2020/202119 1 0 3 1 0 6 4 1 0 0 2 1
2021/202248 1 0 12 14 2 0 1 1 6 7 0 4
2022/2023216 50 43 16 6 12 25 20 25 4 2 6 7
2023/2024242 11 26 32 27 26 28 14 27 0 4 13 34
2024/2025726 56 15 21 28 42 50 358 66 90 0 0 0
Totale 1.261